Patents by Inventor Michelle Nannini

Michelle Nannini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 10092567
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 9717730
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 1, 2017
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Combinations of AKT and MEK inhibitor compounds, and methods of use
    Patent number: 9682082
    Abstract: The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: June 20, 2017
    Assignee: GENENTECH, INC.
    Inventors: Brian Lee, Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20170157124
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Applicant: Genentech, Inc.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Combinations of AKT inhibitor compounds and erlotinib, and methods of use
    Patent number: 9610289
    Abstract: The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: April 4, 2017
    Assignee: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND A CDK4/6 INHIBITOR COMPOUND FOR THE TREATMENT OF CANCER
    Publication number: 20160279142
    Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Lori Friedman, Michelle Nannini, Deepak Sampath, Jeffrey Wallin
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20160228440
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 11, 2016
    Applicant: Genentech, Inc.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Combinations of AKT inhibitor compounds and abiraterone, and methods of use
    Patent number: 9346789
    Abstract: The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: May 24, 2016
    Assignee: Genentech, Inc.
    Inventors: Michelle Nannini, Deepak Sampath
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE
    Publication number: 20160051550
    Abstract: The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: August 26, 2015
    Publication date: February 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • Combinations of AKT inhibitor compounds and erlotinib, and methods of use
    Patent number: 9150549
    Abstract: The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 6, 2015
    Assignee: Genentech, Inc.
    Inventors: Michelle Nannini, Deepak Sampath
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE
    Publication number: 20150064171
    Abstract: The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE
    Publication number: 20140256691
    Abstract: The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 11, 2014
    Applicant: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE
    Publication number: 20140221386
    Abstract: The invention provides A combination of a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: August 7, 2014
    Applicant: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE
    Publication number: 20140155372
    Abstract: The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: June 5, 2014
    Applicant: GENENTECH, INC.
    Inventors: Brian Lee, Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath